The effect of Perasafe® and sodium dichloroisocyanurate (NaDCC) against spores of Clostridium difficile and Bacillus atrophaeus on stainless steel and polyvinyl chloride surfaces

被引:29
作者
Block, C [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel
关键词
Clostridium difficile; Bacillus spp; bacterial; spores; disinfection; disinfectants; biocides; antibiotic-associated diarrhoea; nosocomial infection; environmental decontamination; chlorine compounds; peroxygen compounds;
D O I
10.1016/j.jhin.2004.01.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Clostridium difficile is an important cause of nosocomial diarrhoea. The aim of this study was to evaluate the potential for Perasafe(R), a recently introduced biocide, to contribute to control of C. difficile spores in the patient environment, in comparison with the chlorine-releasing agent sodium dichloroisocyanurate (NaDCC). These agents were evaluated against a water control, in a surface test on stainless steel and polyvinyl chloride (PVC) floor covering, materials commonly found in the hospital environment. The organisms studied were a toxigenic clinical isolate of C. difficile, and Bacillus atrophaeus (formerly B. subtilis var niger). The data indicate that in our in vitro system, Perasafe was significantly more active than NaDCC (1000 ppm available chlorine) against C. difficile spores dried on stainless steel surfaces, and against B. atrophaeus on PVC floor covering material, achieving mean log(10) reduction factors in viable counts of 6 and 5.5, respectively, at 10 min exposures. Perasafe appeared to be less lethal in 10 min exposures to C. difficile spores fixed on PVC floor covering material. In general, 1000 ppm chlorine generated from NaDCC showed lower log(10) reduction factors in viable counts at 10 min, ranging from 0.7 to 1.5, than Perasafe which ranged from 2.7 to 6.0. The potential efficacy of Perasafe in reducing the density of C. difficile spores in the patient environment in hospitals, nursing homes or other long-stay facilities should be evaluated in field studies. (C) 2004 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 24 条
  • [11] ACQUISITION OF CLOSTRIDIUM-DIFFICILE FROM THE HOSPITAL ENVIRONMENT
    KAATZ, GW
    GITLIN, SD
    SCHABERG, DR
    WILSON, KH
    KAUFFMAN, CA
    SEO, SM
    FEKETY, R
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 127 (06) : 1289 - 1294
  • [12] ISOLATION OF CLOSTRIDIUM-DIFFICILE FROM THE ENVIRONMENT AND CONTACTS OF PATIENTS WITH ANTIBIOTIC-ASSOCIATED COLITIS
    KIM, KH
    FEKETY, R
    BATTS, DH
    BROWN, D
    CUDMORE, M
    SILVA, J
    WATERS, D
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1981, 143 (01) : 42 - 50
  • [13] Environmental control to reduce transmission of Clostridium difficile
    Mayfield, JL
    Leet, T
    Miller, J
    Mundy, LM
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (04) : 995 - 1000
  • [14] The estimation of the bactericidal power of the blood
    Miles, AA
    Misra, SS
    Irwin, JO
    [J]. JOURNAL OF HYGIENE, 1938, 38 (06): : 732 - 749
  • [15] Moldenhauer JE, 1996, PDA J PHARM SCI TECH, V50, P391
  • [16] Penna TCV, 2001, BMC INFECT DIS, V1, DOI 10.1186/1471-2334-1-16
  • [17] Reybrouck G, 1999, PRINCIPLES AND PRACTICE OF DISINFECTION, PRESERVATION AND STERILIZATION, 3RD EDITION, P124
  • [18] Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea
    Samore, MH
    Venkataraman, L
    DeGirolami, PC
    Arbeit, RD
    Karchmer, AW
    [J]. AMERICAN JOURNAL OF MEDICINE, 1996, 100 (01) : 32 - 40
  • [19] Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital
    Schwaber, MJ
    Simhon, A
    Block, C
    Roval, V
    Ferderber, N
    Shapiro, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (01) : 9 - 15
  • [20] Evaluation of microbicidal activity of a new disinfectant:: Sterilox® 2500 against Clostridium difficile spores, Helicobacter pylori, vancomycin resistant Enterococcus species, Candida albicans and several Mycobacterium species
    Shetty, N
    Srinivasan, S
    Holton, J
    Ridgway, GL
    [J]. JOURNAL OF HOSPITAL INFECTION, 1999, 41 (02) : 101 - 105